ogt

OGT-IN-2 is a potent O-GlcNAc transferase (OGT) inhibitor. OGT-IN-2 inhibits sOGT and ncOGT with IC50 values of 30 μM and 53 μM, respectively[1]. OGT-IN-2 can be used for the research of articular diseases[1].

OGT 2115 is an inhibitor of heparanase (IC50 = 0.4 µM), an enzyme that cleaves heparan sulfate into glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). OGT 2115 also showed antiangiogenic properties (IC50=1 μM).

OSMI-1 is an O-GlcNAc transferase (OGT) inhibitor (IC50=2.7 μM) that is orally active and cell-permeable. OSMI-1 inhibits protein O-GlcNA acetylation without qualitatively altering cell-surface N- or O- linked glycans.

OSMI-3 is a potent and cell-permeable inhibitor of O-GlcNAc transferase (OGT) for the study of cancer and cardiovascular disease.

OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells), which can be used to study OGT inhibition in different human cell lines.

BZX2 is a novel inhibitor of O-GlcNAc transferase (OGT) activity.

OSMI-2 is a cell-permeable inhibitor of O-linked N-acetylglucosamine transferase (OGT).

(Rac)-OSMI-1 is a racemate of OSMI-1. OSMI-1 is an inhibitor of O-GlcNAc transferase (OGT) (IC50: 2.7 μM). OSMI-1 inhibits protein O-linked N-acetylglucosaminoglycans (O-GlcNAcylation) in mammalian cell lines and does not qualitatively alter cell surface N- or O-linked glycans.

Sinbaglustat (OGT2378) (OGT2378) is a dual inhibitor of glucose ceramide synthetase (GCS) and non-lysosomal glucose ceramidase (GBA2).Sinbaglustat is an orally administered N-alkyl iminosugar that crosses the blood-brain barrier.Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of central neurodegenerative disorders associated with lysosomal dysfunction. Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of lysosomal dysfunction-related central neurodegenerative diseases.

PG 34 is a structural analogue of OSMI-1 and a weak inhibitor of O-GlcNAc translocase (OGT) with an IC50 value of 68 μM.

BZX1 is a novel inhibitor of O-GlcNAc transferase (OGT) activity.

Miglustat (NB-DNJ) is an alkylated product of imino sugar deoxynojirimycin.It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Miglustat hydrochloride (N-Butyldeoxynojirimycin hydrochloride) is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease.

UDP-GlcNAc Disodium Salt (UDP-α-D-N-Acetylglucosamine Disodium Salt) is a nucleotide sugar. It is synthesized from glucose via the hexosamine biosynthetic pathway (HBP).